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There is growing recognition of the potential value of human induced pluripotent stem cells (hiPSC) for understanding disease and iden-
tifying drugs targets. This has been reflected in the establishment of multiple large-scale hiPSC initiatives worldwide. Representatives of
these met recently at a workshop supported by theWelcome Trust in the UK and in a focus session at the 2014 ISSCR annual meeting in
Vancouver. The purpose was to discuss strategies for making thousands of hiPSC lines widely available with as few restrictions as possible
while retaining financial viability and donor privacy. The outcome of these discussions is described here.Introduction
The ability to generate human induced pluripotent stem
cells (hiPSCs) by direct reprogramming of somatic cells
by simple overexpression of transcription factors initiated
a paradigm shift in biomedical science (Takahashi et al.,
2007; Yu et al., 2007). In just a few years, hiPSCs have
opened new fields of investigation not only in cellular re-
programming itself but also in creating human models of
inherited diseases for basic research in pathological mech-
anisms and drug target discovery. The increasing numbers
of grant applications and publications that include hiPSCs
(>7000 manuscripts have been published since 2007) are
evidence of how these cells have captured the imagination
of those both inside and outside this rapidly evolving field.
Several large-scale initiatives have already been established
to serve this growing interest and facilitate hiPSC pro-
duction for studying monogenic and genetically complex
disorders and understanding the causes of disease pre-
disposition in the context of stratified medicine. Collec-
tively, these large-scale initiatives plan to derive more
than 100,000 hiPSC lines from cohorts of patients and
healthy donors in Europe, North America, Brazil, China,
Japan, South Korea, and Australia (Tables 1 and S1), the
focus being largely on their in vitro applications in disease
modeling, genetic variation, and drug development. Over-
all, these initiatives aim to create opportunities to address
major health issues for conditions with few treatment
options that lack human disease models or for which pri-
mary biopsies are difficult to access. These conditions
include neurodegenerative and neurocognitive disorders,
metabolic syndromes, and heart failure. To ensure that
they are an appropriate return on investment, the banks
are attempting to coordinate their activities with respect
to donor-informed consent, material transfer agreements
to academia and industry, standards of culture and charac-Stem Cellterization, and availability of donor medical history
(Figure 1).
Most programs intend to create biorepositories of well-
characterized hiPSC lines from different disease groups as
well as healthy control individuals. The coordination of
these efforts, as at the Wellcome Trust and ISSCR work-
shops, to discuss the conceptual, technical, ethical, and
commercial challenges associated with the derivation of
such high numbers of hiPSC lines, is unprecedented.
This report summarizes the emerging plans to establish
permanent international coordination for sharing re-
sources, knowledge, and standards on hiPSC derivation
and characterization. The ambition is that hiPSC lines in
the repositories will become a shared, worldwide research
resource.
Generation of hiPSC lines
Among the issues considered were the different technolo-
gies available for deriving hiPSCs.
Reprogramming Methods
This was considered themost important technical decision
to be made by large-scale hiPSC initiatives, because the
quality of banked lines may be highly dependent on the
method used. Several methods are currently available to
generate hiPSCs from somatic cells and are usually based
on introducing the transcription factors SOX2, c-MYC,
OCT4, KLF4 and/or LIN28. Some methods introduce the
transgenes on viral vectors, resulting in their integration
into the genome of target cells. Other approaches use con-
ditional integrating vectors that allow subsequent removal
of the transgenes using recombinases such as Cre, although
this leaves a residual loxP site (Woltjen et al., 2009). ‘‘Scar-
less’’ reprogramming is widely regarded as preferable, so
that the most common approaches now used are non-
integrating and rely on adenoviral (Stadtfeld et al., 2008),Reports j Vol. 3 j 931–939 j December 9, 2014 j ª2014 The Authors 931
Table 1. Major Large-Scale hiPSC Initiatives
Initiatives Location
Cell Type /Derivation
Technology Characterization Assays Open Access hiPSC Lines
Human Induced
Pluripotent Stem
Cells Initiative
(HIPSCI)
United
Kingdom
Skin fibroblasts
Sendai virus
Mycoplasma
PluriTest
Phenotypic assays
for 3 germ layers
Genotype chip
Gene expression
RNA sequencing
Exome sequencing
CHIP sequencing
Methylome
Proteomics
Open access data for
some normals, managed
access for disease and
remaining normal
samples
Cell banking with ECACC
hiPSC lines from 500 normal and
500 diseased donors
StemBANCC/IMI European
Union
Skin biopsies
and hair sample
Sendai virus
Pathogen testing
PluriTest
Flow cytometry for Nanog
SNP array
Whole exome sequencing
EB differentiation
Proteomics
Not-for-profit, research
for academia and industry
1500 hiPSC lines from 500 donors
including healthy controls, diabetic
patients, adverse drug responders,
neurodysfunctional disorders and
neurodegenerative disorders
Drug screening, public-private
partnership
California Institute
for Regenerative
Medicine
United
States,
California
Skin fibroblasts
and PBMC
Episomal
plasmids
Pathogen testing
Mycoplasma
Pluripotency markers
SNP Illumina Array
PCR for episomal
integration
Available for research and
commercial use
Derived by CDI and banked
by Corriel
Additional fees and
royalties for
commercial use
9000 lines from 3000 individuals
and 11 diseases
Lines for disease modeling, target
discovery, drug discovery and R&D
New York Stem
Cell Foundation
United
States,
New York
Skin fibroblasts
mRNA
reprogramming
25 pluripotent genes and
100 genes on scorecard
assay on EB
Copy number variation
analysis
Differentiation of
beta-like cells
Open access Repository of 2500 hiPSC lines
representing diversity of US and
rest of the world
Generation of hiPSC lines for
neurodegenerative diseases and
diabetes
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Meeting ReportSendai virus (Fusaki et al., 2009), or episomal plasmid vec-
tors (Yu et al., 2009) to deliver the reprogramming genes.
Other nonintegrating methods use synthetic modified
RNAs (Warren et al., 2010) and protein-based reprogram-
ming (Kim et al., 2009). These methods, however, still
vary in efficiency, complexity, labor required, and compat-
ibility with different somatic cell types.
Most large-scale hiPSC initiatives prefer nonintegrating
methods, in order of preference: episomal plasmids, Sendai
virus, and modified RNAs. These approaches all work effi-
ciently on various somatic cell types, and the resulting
hiPSC lines have been widely validated by many research
groups. However, each method has specific limitations:
episomal plasmids have lower reprogramming efficiencies
and the potential for residual plasmid integration, Sendai
viruses require higher biosafety containment levels and
are relatively costly, and mRNA reprogramming is labor
intensive, requiring repeated (daily) transduction and
costly Pluriton medium.932 Stem Cell Reports j Vol. 3 j 931–939 j December 9, 2014 j ª2014 The AThe workshop consensus was that despite some short-
comings, reprogramming methods are already adequate
for the purpose, with new methods rarely being more
efficient than the four factors originally described by
Yamanaka and colleagues. Furthermore, new methods as
published have rarely been validated on the variety of
cell cultures available from broad human cohorts, and
thus their applicability to large-scale programs is an open
question. It was concluded that an international initia-
tive could accelerate validation of different methods by
creating a network of key experts to test them and dissem-
inate the resulting information to benefit the entire field.
Another issue discussed was how many cell lines should
be derived and characterized per donor. Several initiatives
are deriving three clonal lines per donor while character-
izing only one. However, others prefer to derive only one
polyclonal cell line that can be later subcloned into indi-
vidual sublines. Later subcloning has the advantage of
reducing the number of lines maintained and thus theuthors
Figure 1. Workflow for Large-Scale Ini-
tiatives and Requirements for Standardi-
zation
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ating potentially heterogeneous populations of hiPSCs
with diverse genetic anomalies, epigenetic memory, and
capacity for differentiation.
Somatic Cell Type
Which somatic cell type to reprogram is another important
consideration for large-scale hiPSC derivation. A wide vari-
ety of cell types from different primary tissues has already
been used to generate hiPSCs, and several studies suggest
that they could have variable differentiation potentials
and oncogenic risk (Ghosh et al., 2010; Miura et al.,
2009). Furthermore, early passage hiPSCs could retain
some ‘‘epigeneticmemory’’ of the somatic cells fromwhich
they were derived. This phenomenon has been associated
with abnormal reprogramming of the DNA methylation
signature of somatic cells. Epigenetic memory may have
major consequences for the capacity of hiPSCs to differen-
tiate as shown by the substantial variability in teratomaStem Cellforming potential of iPSC lines derived from different adult
mouse tissues (Miura et al., 2009). However, several other
studies suggest that epigenetic memory can decrease over
time in culture (Nishino et al., 2011). The consensus in
the workshops was that hiPSCs should be passaged at least
10 times after first appearance to stabilize the pluripotent
phenotype and ensure genetic stability. Characterization
and differentiation at early passage (<10) was reported to
be problematic and thus was systematically excluded in
most of the production pipelines. However, the experience
was that this precaution did not resolve variability between
hiPSC lines derived from different donors; this was identi-
fied as a major challenge when working simultaneously
with a large number of lines. The reasons for this variability
remain unclear but were thought to originate from a com-
bination of factors including genetic background (Rouhani
et al., 2014), abnormal reprogramming, and epigenetic
memory.Reports j Vol. 3 j 931–939 j December 9, 2014 j ª2014 The Authors 933
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hiPSC initiatives have chosen to use somatic cell types
based on ease of accessibility and reprogramming effi-
ciency. To date, dermal fibroblasts have been the most
commonly reported in the literature and bymost of the ini-
tiatives because they reprogram efficiently, are easily iso-
lated from skin biopsies as small as 2 mm, and can be cry-
opreserved and banked before reprogramming. This is
important because the creation of a fibroblast bank pro-
vides the opportunity to use different reprogramming
methods at a later date, should this be necessary. Another
cell typewidely used by large-scale initiatives are peripheral
blood mononuclear cells (PBMC), which can often be
collected more easily from patients, especially infants,
than biopsies, and may be available as frozen samples
already stored in cell repositories and (cord) blood banks.
The development of robust protocols for reprogramming
blood cell is potentially game changing, making it possible
to develop hiPSC initiatives that leverage very large exist-
ing collections, such as that of the NIMH Repository and
Genomics Resource (NRGR, https://www.nimhgenetics.
org) and the NINDS Repository at Coriell (https://catalog.
coriell.org/1/NINDS) with tens of thousands of specimens
from subjects that have extensive clinical phenotypic
data associated over years of study. Kidney epithelial cells
found in urine are also of increasing interest because they
are entirely noninvasive to collect.
Culture System
Ideally, methods to generate and expand hiPSCs would be
fully defined and not require xenoreagents. Nevertheless,
Knockout Serum Replacement medium in combination
with mouse embryonic feeder cells has been most widely
used to date. However, most initiatives are nowmoving to-
ward feeder free systems and chemically defined media
such as the Essential 8 (containing eight defined factors)-
vitronectin substrate culture system (Chen et al., 2011).
The increasing interest in xeno-free, chemically defined
media and substrates is motivated by the wish to improve
robustness, reproducibility, and compatibility with clinical
or good laboratory practice (GLP) applications. On the
other hand, because the methods are relatively new, it is
not yet clear whether there may be additional risks, for
example, associated with increased genetic or epigenetic
instability. The workshop delegates highlighted the im-
portance of identifying the advantages and drawbacks of
each system and of the stem cell community reaching a
consensus. Indeed, the development of common culture
practices among large-scale initiatives would facilitate
hiPSC line standardization and reproducibility of experi-
ments between laboratories.
Automation
Automation systems are increasingly viewed as providing
opportunities to improve standardization in the generation934 Stem Cell Reports j Vol. 3 j 931–939 j December 9, 2014 j ª2014 The AofhiPSC lines. Several initiatives areexploring this approach
for the generation of hiPSC lines. The New York Stem Cell
Foundation has already automated the derivation of hiPSCs
by mRNA reprogramming in 96-well plates using liquid-
handling robots. This system also allows maintenance and
expansion of hiPSCs as well as hiPSC differentiation into
pancreatic beta-like cells. Other groups are investigating
other automated culture systems with sensors to allow
online monitoring and characterization of hiPSCs via
metabolomics and Fourier Transform Infrared Spectroscopy
(FTIR).
Characterization
Proper characterization of hiPSCs and what the criteria for
this should be was identified as a major challenge by all
the initiatives with delegates attending the workshop.
Indeed, the main objective of these initiatives is to
generate banks of high-quality hiPSC lines for a broad
spectrum of users and projects. However, the diversity of
assays in current use, lack of consensus on the key criteria
that define utility for purpose, and budget constraints that
limit implementation of expensive assays still make it
difficult to define the pluripotent stem cell profile that
banks can be expected to make available to users. Further-
more, identifying the best hiPSC lines remains a challenge
due to still-limited understanding of the mechanisms
controlling self-renewal and differentiation capacity. The
consensus was therefore to divide characterization into
four categories.
Pluripotency
Assays to validate the pluripotent state of hiPSCs vary in
time required, cost, and accuracy. hiPSCs are usually first as-
sessed by morphology; this approach is routinely used by
themajority of the initiatives as the first step in distinguish-
ing fully versus partially reprogrammed lines. The next evi-
dence is the expression of markers associated with pluripo-
tency such as OCT4, NANOG, SOX2, and TRA-1-60/SSEA-
3 by immunostaining, FACS (for cell surface markers) or
q-PCR (for transcription factors). It was agreed that this suf-
fices to designate cells as reprogrammed. Although more
complex in silico analyses of gene expression profiles
(for example, PluriTest:Mu¨ller et al., 2011) canprovide com-
plementary information, the outcome rarely contradicts
morphological and immunostaining data. Of note, though,
is that PluriTest and similar algorithms will give a high plu-
ripotency score to teratocarcinoma tumor cells and do not
report differentiation potential.
Differentiation Capacity
True hiPSC lines should form derivatives of all three germ
layers. Teratoma formation is historically the best and
most rigorous method for demonstrating this, but as an
assay it is not quantitative. Additionally, it would be
practically impossible, extremely costly, and ethicallyuthors
Stem Cell Reports
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thousands of hiPSC lines and derivative clones. There was
general agreement that teratoma assays should preferably
be abandoned and that other higher-throughput, quan-
titative approaches, preferably in vitro based, need to be
developed. The International Stem Cell Initiative (ISCI3)
is addressing this issue by comparing the outcome of
in vitro protocols including embryoid body differentiation
under defined conditions, assessed by gene expression
data; the PluriTest bioinformatics analysis of gene expres-
sion in undifferentiated hiPSCs; and a rapid immuno-
staining approach, with quantitative analysis of hiPSCs
differentiating in teratomas. Differentiating hiPSC lines
in vitro into derivatives of the three germ layers and
monitoring efficacy by immunostaining for specific cell
types may however be sufficient for most publication
purposes, although none of the current methods can
predict the ability of undifferentiated hiPSCs to differen-
tiate into specific cell types, such as dopaminergic neu-
rons or hepatocytes, prospectively. Additionally, the need
to share and standardize differentiation protocols was
recognized.
Genetic Stability
Genetic stability is becoming increasingly important
among criteria for hiPSC line release because the cells
regularly display karyotypic abnormalities in culture,
frequently on specific chromosomes. Quality assurance
should thus include systematic and regular karyotyping.
However, conventional methods of karyotyping, such as
G banding or chromosome painting, are time and resource
consuming and thus impossible to use in pipelines produc-
ing large numbers of independent hiPSC lines. All of the
initiatives plan to use genome arrays such as high-resolu-
tion SNP (single nucleotide polymorphism) and CGH
(comparative genome hybridization). Exceptionally, the
Wellcome Trust-funded HIPSCI program will perform
exome sequencing on hiPSC lines as basic characterization,
taking advantage of the unique sequencing capability of
the adjacent Sanger Institute. Nevertheless, the resolution
of the genome-wide methods (SNPs, CGH, Exome-Seq)
can be problematic because major chromosome rearrange-
ments may be missed if present in only a small fraction
of the cell population. Each initiative has observed that
genetic instability occurs naturally in hiPSCs and that
10%–30% of the lines generated could carry small amplifi-
cations/deletions. Studies have shown that at least some of
the copy number variations (CNV) detected in hiPSCs may
be due to mosaicism, residing in subpopulations of the
source cells used to derive the hiPSCs, rather than arising
as a consequence of the reprogramming methodology.
Therefore, the origin and significance of these changes
remain problematic and the consensus was that onlymajor
chromosomal rearrangements would likely be detrimentalStem Cellto in vitro applications. In addition, coordinated efforts are
still necessary to collect genetic data of thousands of lines
and thus enable a precise evaluation of the genetic changes
specifically associated with reprogramming and/or in vitro
expansion.
Epigenetic Stability
This feature of hiPSCs remains largely unexplored because
it requires costly genome wide analyses of histone modi-
fications and DNA methylation. Furthermore, the epige-
nome is often considered properly reprogrammed as long
as the gene expression profile of hiPSC lines conform
with that of other validated pluripotent stem cells lines.
The HIPSCI program is the only initiative that will provide
a full epigenetic profile on all of the 1000 hiPSC lines it will
generate. This information will be invaluable to define the
importance of the epigenetic profile on the capacity for
differentiation and to establish how genetic background
can influence epigenetic state.
Quality Control and Distribution
The immense resources required to generate large-scale
collections of hiPSCs dictate that the most stringent
quality control standards be applied to the cells before
they are made widely available. The meeting participants
agreed that standardized characterization should include
many of the criteria mentioned above, as well as measure-
ment of cell viability after thawing of cryopreserved cells,
sterility, the absence of human pathogens (HIV-1, Hep-B,
and Hep-C at a minimum), and genomic profiling. It is
also critical to track cell identity to guard against potential
specimen mixups or contamination by processing each
hiPSC line on SNP identity panels. Historically, reposi-
tories such as RUCDR (http://www.rucdr.org) have per-
formed all of these functions for many large-scale human
genetics initiatives involving the use of nucleic acids, cell
lines, and other biomaterials collected and processed
from study participants. The use of centralized facil-
ities for the identification, characterization, expansion,
and distribution of hiPSC lines will be a key factor in
facilitating their dissemination globally as high quality
resources.
Ethical Consent/Donor Identification and
Recruitment
During the workshops it was agreed that ethical consent
forms acceptable for worldwide use would be ideal but
that this would be practically impossible to achieve because
each country has different regulatory landscapes. Never-
theless, key aspects that should be carefully considered
when preparing ethical consent forms were identified
because a major objective of the hiPSC initiatives is to
bank lines that could be widely distributed. Indeed, the
free distribution and open access of the hiPSC lines andReports j Vol. 3 j 931–939 j December 9, 2014 j ª2014 The Authors 935
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tiatives to have maximal impact and return on investment
for the scientific and industrial communities. Ethical
consent needs to capture this and allow full and open
access to lines and data. The availability of such data
would provide vital tools for optimizing rational and
economical selection of cohorts for downstream studies.
Furthermore, linking medical records that document
disease history and medication responses to hiPSC lines
via active links safeguarded by firewall protection would
create a valuable source of information for disease
modeling and drug screening activities. Also, the possibil-
ity of recontacting the donor to request additional tissue
samples or updates on health status would be of great value
in studying disease progression. Importantly, hiPSC lines
and data would ideally be available to academic and non-
academic institutions. This was regarded as essential to
raise interest and support from industry for the creation
of hiPSC banks.
Finally, because hiPSC lines represent a unique system to
study human genetics and corresponding phenotypes,
several studies are already performing genome wide ana-
lyses such as whole genome sequencing. These data will
allow the identification of genetic variations associated
with particular diseases and greater insights into the impli-
cations for health in a way not possible in studying mice,
simply because relevant SNPs and variant sequences are
not necessarily conserved. This could increase understand-
ing of the genetic basis of individual variability and its
impact on disease onset and severity, thereby informing
strategies to detect, treat, and prevent disease. Thus, con-
sent forms need to enable open or controlled access to
(deidentified) genetic data. Although, recent reports have
shown that genome-wide data could be used to identify do-
nors even though all of the direct identifiers have been
removed, measures such as deleting any sequence related
to the Y chromosome could be implemented to mitigate
this risks and support open access and the distribution of
the hiPSC lines and genomic data to the wider community.
These points need to be explored in greater depth in the
context of local legal and social frameworks and evolving
technologies.
Intellectual Property
The intellectual property (IP) landscape for hiPSCs is com-
plex, with several institutions owning patents on aspects of
iPSC generation, expansion, and use, each of which could
have major impacts on the freedom to use lines by com-
mercial and academic investigators. The four ‘‘Yamanaka
factors’’ are licensed by iPS Academia Japan. This gives
full freedom to operate for academic laboratories, while
reasonable license fees can be requested for commercial ac-
tivity. In addition, Sendai virus is commercially available936 Stem Cell Reports j Vol. 3 j 931–939 j December 9, 2014 j ª2014 The Athrough Life Technologies under license from DNAVEC.
hiPSC lines generated with this last method are covered
by a strong Limited Use Label License (LULL) associated
with an important IP reach through for a number of appli-
cations. Direct negotiations are usually required and each
user needs to establish his/her own agreement with the
owner of the IP. The use of the episomal plasmids appears
to be less restrictive. Nevertheless, this method seems to
be covered by several patents owned by different institu-
tions and companies including Cellular Dynamics, which
makes freedom to operate in deriving hiPSCs using
episomal plasmids rather unclear. Importantly, patents
may cover not only the hiPSC lines themselves but also
their direct applications.
Another area of concern centers on potential restrictions
associated with the use of tools such as nucleases and fluo-
rescent reporters to make derivatives of the original hiPSC
lines. Technology providers holding the rights to these
tools often invoke IP reach through rights thatmay present
obstacles for users, academic and industrial, in using or pat-
enting derivative lines in the future. These obstacles may
even impede the ability of not-for-profit repositories to
distribute the lines affordably to end users. However, with
respect to differentiated cells generated from hiPSCs, the
situation remains unclear: several institutions, including
the NIH, consider that differentiated derivatives are not
covered by the claims of hiPSC derivation methods. This
is a crucial point on which the international community
should take a balanced view to avoid unnecessary restric-
tion that could damage the widespread use of hiPSCs for
drug screening and cell based therapies. Most of the initia-
tives strongly recommended that owners of intellectual
property adopt a transparent and consistent position for
use of their technology that would not impair the advances
of the hiPSC field.
Genome Editing
Recent advances in genome editing now allow rapid and
efficient introduction of genetic modifications in hiPSCs.
Gene deletion, targeted introduction of fluorescent or
other reporters and introduction or correction of specific
mutations to generate isogenic pairs of disease and control
lines, differing only in the mutation of interest, are all
feasible. Transcription activator-like effector nucleases
(TALENs) and clustered regularly interspaced short palin-
dromic repeat (CRISPR)/Cas systems are preferred ap-
proaches used by several large-scale initiatives. Notably,
the Wellcome Trust Sanger Institute is developing a
high throughput pipeline to generate heterozygous and
homozygous mutant hiPSC lines to target more than
1000 genes. The Gladstone Institute in San Francisco and
Harvard University in Boston are likewise using TALENS
and CRISPR/Cas to generate a large number of hiPSC linesuthors
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disorders.
An important issue discussed in the workshops was the
nature of controls and how to avoid misinterpretation
associated with natural variability (or noise) between
different hiPSC lines (Rouhani et al., 2014). Generating
genetically corrected isogenic hiPSC lines would be time
consuming and expensive for the initiatives, although
increasingly, published studies indicate real interest in
this approach. An alternative could be panels of hiPSC
lines from healthy donors that could be widely available
as controls, much like the original human embryonic
stem cell (hESC), lines, H1, H7 and H9, are widely used as
benchmarks, and that could also be used to introduce spe-
cific mutations. Workshop delegates viewed genome edit-
ing as a complementary alternative to hiPSCs derived
from patients with monogenetic disorders because this
bypasses the need to generate new lines and ensures a
spectrum of mutations on a single genetic background.
However, complex diseases involving several genes would
bemore challenging and there would be no data on disease
severity available. Furthermore, diverse genetic (and
ethnic) backgrounds might be necessary to fully under-
stand disease mechanisms. Thus, the development of
robust genome editing methods represents an important
evolution for the stem cell field, and these methods are
likely to be frequently used in combination with hiPSC
derivation from patients in the near future.
Discussion
The topics discussed during the meetings not only covered
the challenges that large-scale hiPSC initiatives are facing
but also considered the issues that many groups have
encountered over the past 7 years since their first discovery.
These challenges range from technology of derivation,
characterization, ethics, and IP to genome editing tools.
As a result, a set of measures was suggested to advance
the field.
Development of Reference hiPSC Panel
The distribution to the community of a panel of 10 hiPSC
lines generated by different institutions in the leading
countries for research in this area would be extremely use-
ful to standardize protocols between laboratories, for the
validation of new technologies, and also for experimental
reproducibility. These hiPSC lines would have to be gener-
ated under broad ethical consent, fully characterized for
their pluripotent state and capacity to differentiate into
relevant cell types. Furthermore, the genetic stability
and the compatibility of these lines with genome editing
would have to be documented. Discussion and planning
have already been initiated between the Wellcome
Trust Sanger Institute and other organizations such as
the NIH.Stem CellTraining
Training was identified as a clear challenge in the field.
There is still a paucity of institutions providing training
to derive, maintain, characterize, and differentiate hiPSCs,
although this is increasing as the field expands. Further-
more, there is a need for coordination among individual
groups using different methodologies that result in diver-
gent standards and sometimes difficulties in reproducing
experimental outcomes. Ideally, training would be central-
ized to leading institutions, with the trainers using com-
mon methods and approaches. Concerning differentia-
tion, training could be given by the groups developing
the methods to ensure reproducibility. Organization of
such training will require significant and coordinated sup-
port from funding agencies.
Common Ethics Policy
Although it would be desirable that a common, interna-
tionally recognized, consent template to derive hiPSCs
was used that covered conditions of tissue donation (altru-
istic, voluntary, no donor benefit or feedback, academic
and nonacademic users), it was considered unlikely that
this could be agreed because of divergent international reg-
ulations and cultures and also local ethical committees.
Synchronized IP
A coordinated approach to negotiate licenses withmajor IP
owners would significantly benefit the field. Repositories
will play a key role as honest brokers in facilitating the
implementation of these agreements so that both the pro-
viders and end users’ needs, scientific and economic, are
accommodated. Exchange of information on IP and license
agreements signed by the initiatives would increase trans-
parency and understanding of the necessary steps and im-
plications on signing such documents. Another important
consideration is the definition of academic versus nonaca-
demic (commercial) research and profit versus not-for-
profit use. It was pointed out during the meetings that
there are several differences within Europe, US, and other
countries. The attendees proposed that several categories
of commercial exploitation should be defined and that
the licenses should be dealt with accordingly. Regarding
differentiation, the consensus was that differentiated cells
should not be covered by the IP associated with methods
of derivation, following the NIH perspective. The restric-
tive nature of licensing requirements attached to tools, re-
agents, and technologies will be a primary factor in driving
the choices made in the earliest stages of planning large-
scale projects involving hiPSCs. By virtue of their size and
leadership position in the field, the initiatives will have
considerable influence in driving this discussion within
the community.
hiPSC Registry/Portal
The participants in both meetings agreed that the creation
of large, well-characterized banks of hiPSCs must beReports j Vol. 3 j 931–939 j December 9, 2014 j ª2014 The Authors 937
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resources that the global research community can use to
easily filter and identify cell lines of interest. This could
minimize the use of lines without appropriate background
history, ethical consent, and poor characterization. Addi-
tionally, it would increase the speed of locating lines
with a specific genotype or disease of interest and improve
the exchange of information between the different
initiatives. The creation of effective databases relies on
achieving consensus agreement on common data ele-
ments (disease subcategory trees, representing patient
selection criteria like gene variants, reprogramming and
QC methods, age/gender, consent for industry use, etc.)
for structuring the collections so that they can be most
effectively searchable. The adoption of standardized
nomenclature for hESC and hiPSC lines would aid in
this effort as well (Luong et al., 2011). The need to coordi-
nate this activity at the earliest stages was recognized,
given the technical challenges in its implementation. In
addition, if available as a website, this could be used as a
discussion forum to collect protocols and troubleshot on
a day-to-day basis. The hESReg database, originally estab-
lished to provide information on all hESC lines used in
EU projects, is now being expanded to include hiPSC
lines (http://www.hescreg.eu). All EU-funded projects are
required to register the hiPSC lines they use or generate
or to use only pre-registered lines. If more widely imple-
mented, this would serve as a useful information interface
with the user community. A number of other efforts
are underway, including eagle-i (https://www.eagle-i.net),
the Neuroscience Information Framework (http://www.
neuinfo.org), and the International Stem Cell Registry
(http://www.umassmed.edu/iscr). The hiPSC initiatives
were all willing to promote open exchange of hiPSC lines
from their banks.
Conclusion
Large-scale hiPSC initiatives are likely to generate the
majority of the lines that will become available worldwide
in the coming decade. Their coordination will be essential
to fully exploit these unique resources. The workshop
in Hinxton, UK, and the focus session at the 2014
ISSCR annual meeting clearly identified the challenges to
achieving this major task and the benefits of establishing
international coordination and optimizing these resources
(Figure 1). The key objectives of this coordinationwould be
(1) to define technical standards for derivation and charac-
terization of hiPSC lines, (2) create a panel of fully validated
standard hiPSC lines originating from different centers, (3)
standardize training between the different centers, (4)
coordinate ethics/IP among the different initiatives, and
(5) centralize resources and information on hiPSC lines
derived by each initiative.938 Stem Cell Reports j Vol. 3 j 931–939 j December 9, 2014 j ª2014 The ASUPPLEMENTAL INFORMATION
Supplemental Information includes two tables and can be found
with this article online at http://dx.doi.org/10.1016/j.stemcr.
2014.11.006.
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